# OnCo record acalabrutinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/acalabrutinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "acalabrutinib" ;
  schema:name "Acalabrutinib"@en ;
  schema:description "Acalabrutinib is a cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen."@en ;
  schema:url <https://onco.cc/drugs/acalabrutinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acalabrutinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q23668732> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Acalabrutinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule covalent BTK inhibitor (second generation)" ;
  schema:alternateName "Calquence" ;
  onco:approval "US 2017: Relapsed MCL (accelerated)", "US 2019: CLL/SLL, first-line and relapsed (ELEVATE-TN, ASCEND)", "US 2026: Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)" ;
  onco:acceleratedApproval "US 2017-10-31: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy" ;
  onco:acceleratedApprovalConfirmed "US 2025-01-16: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll-treatment-naive/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/elevate-tn/>, <https://onco.cc/trials/amplify/>, <https://onco.cc/trials/nct04529772/>, <https://onco.cc/trials/nct05952024/>, <https://onco.cc/trials/nct02213926/>, <https://onco.cc/trials/nct05951959/>, <https://onco.cc/trials/nct02180711/>, <https://onco.cc/trials/nct03932331/>, <https://onco.cc/trials/nct04502394/>, <https://onco.cc/trials/nct07029737/>, <https://onco.cc/trials/nct04075292/>, <https://onco.cc/trials/nct07277231/>, <https://onco.cc/trials/nct06428019/>, <https://onco.cc/trials/nct02477696/>, <https://onco.cc/trials/nct02970318/>, <https://onco.cc/trials/nct07024706/>, <https://onco.cc/trials/nct02180724/>, <https://onco.cc/trials/nct05057494/>, <https://onco.cc/trials/nct04662255/>, <https://onco.cc/trials/nct02717611/>, <https://onco.cc/trials/nct02029443/>, <https://onco.cc/trials/nct02972840/> .